Hepatitis D Drug Discontinuation Linked to Relapse Risk
Clinical trial data found many patients experienced viral recurrence after stopping long-term bulevirtide treatment.
Updated on Sept. 29, 2026 in Diseases — General
Live Poll
Do you trust clinical trial findings that support periodic interruptions in long-term medical treatments?
Researchers published clinical trial findings on March 1, 2026, revealing that stopping bulevirtide treatment for hepatitis D frequently led to viral relapse. Only about 20% of study participants maintained undetectable levels of the virus after 96 weeks of post-treatment follow-up.
Why it matters
These findings highlight significant risks associated with ending therapy, including potential spikes in liver enzymes and the necessity for hospitalization in some cases. Understanding these outcomes is essential for patients and clinicians evaluating the long-term management of chronic hepatitis D.
In the MYR301 trial, 150 patients received various bulevirtide regimens for 144 weeks, with approximately 57% completing 96 weeks of follow-up. While 36% of those who were undetectable at the end of treatment did not relapse, 93% of all relapses occurred by the 24th week of follow-up.
The players
MYR301 trial
A Phase 3 clinical study that evaluated the efficacy and safety of different bulevirtide dosing regimens for patients with hepatitis D.
The details
Bulevirtide works by blocking the viral entry receptor on liver cells, preventing the hepatitis D virus from infecting new cells. The study demonstrated that after discontinuing the drug, 41% of patients experienced ALT levels rising above five times the upper limit of normal, indicating significant liver stress. These post-treatment flares prompted hepatic serious adverse events in 20 patients and required four hospitalizations.
Timeline
Week 24: 84% of partial responders reached virologic response.
Week 144: Treatment concluded for the 150 participants in the clinical trial.
Follow-up week 24: 93% of post-treatment relapses had occurred by this point.
Follow-up week 96: Researchers assessed final outcomes for study participants.
Health Landscape
This research provides essential context for the long-term management of chronic hepatitis D, a condition where treatment duration remains a central clinical challenge. It marks a departure from standard, fixed-duration therapeutic approaches by illustrating the complex risks associated with treatment cessation.
Patients currently undergoing bulevirtide therapy should prioritize consistent monitoring, as the data indicates that most relapses happen within the first six months after stopping. It is vital to discuss any proposed changes to treatment regimens or concerns about liver enzyme levels with your physician.
The takeaway
The data confirms that stopping bulevirtide poses a high risk of viral relapse and potential liver inflammation in the short term. Always consult your specialist to understand the specific risks and monitoring protocols required before making decisions about discontinuing long-term viral therapy.
Further reading
For broader information on managing chronic conditions, explore our Diseases — General section.
Source note: This article includes information reported by Ajmc.
Live Poll
Do you trust clinical trial findings that support periodic interruptions in long-term medical treatments?
